

This listing of claims will replace all prior versions,
and listings, of claims in the application:

LISTING OF CLAIMS:

Claims ~~1-39~~ are canceled.

Add the following new claims:

3, Claim 40. (new): An isolated, substantially purified nucleotide sequence, comprising SEQ ID NO: 3 and homologous sequences thereof, wherein said homologous sequence exhibits at least 70% homology, said nucleotide sequence is in a screening system and is a marker for compounds exhibiting insulin regulating properties.

Claim 41. (new): The nucleotide sequence according to claim 40, wherein said sequence comprises SEQ ID NO:3.

Claim 42. (new): The nucleotide sequence according to claim 40, wherein said sequence consists of SEQ ID NO:3.

Claim 43. (new): The nucleotide sequence according to claim 40, wherein said sequence is a marker for thiazlidinedione (TZD) compounds.

RECEIVED
JUN 03 2003
TC 1700

Claim 44. (new): The nucleotide sequence according to claim 40, wherein said sequence is a marker for adipocyte specific insulin regulating substances.

3'
Claim 45. (new): The nucleotide sequence according to claim 40, wherein said sequence exhibits at least 98% homology.

Claim 46. (new): The nucleotide sequence according to claim 40, wherein said sequence exhibits at least 90% homology.

Claim 47. (new): An isolated, substantially purified nucleotide sequence, comprising SEQ ID NO:3 and homologous sequences thereof, wherein said homologous sequences exhibit at least 70% homology, wherein said nucleotide sequence is coupled to a reporter system and is a marker for compounds exhibiting insulin regulating properties.

Claim 48. (new): The nucleotide sequence according to claim 47, wherein the reported system is a fluorescent reporter molecule.

Claim 49. (new): The nucleotide sequence according to claim 47, wherein said sequence comprises SEQ ID NO:3.

Claim 50. (new): The nucleotide sequence according to claim 47, wherein said sequence consists of SEQ ID NO:3.

3
D
cont

Claim 51. (new): The nucleotide sequence according to claim 47, wherein said sequence is a marker for thiazlidinedione (TZD) compounds.

Claim 52. (new): The nucleotide sequence according to claim 47, wherein said sequence is a marker for adipocyte specific insulin regulating substances.

Claim 53. (new): The nucleotide sequence according to claim 46, wherein said sequence exhibits at least 98% homology.

Claim 54. (new): The nucleotide sequence according to claim 46, wherein said sequence exhibits at least 90% homology.

Claim 55. (new): An isolated, substantially purified nucleotide sequence, comprising SEQ ID NO:3, said nucleotide sequence is in a screening system and is a marker for compounds exhibiting insulin regulating properties.
